Premium
CD10‐positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma
Author(s) -
Clarke Loren E.,
Frauenhoffer Elizabeth,
Fox Edward,
Neves Rogerio,
Bruggeman Richard D.,
Helm Klaus F.
Publication year - 2010
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.2010.01532.x
Subject(s) - atypical fibroxanthoma , dermatofibrosarcoma protuberans , pathology , tissue microarray , leiomyosarcoma , immunohistochemistry , dermatofibrosarcoma , medicine , differential diagnosis , ki 67 , basal cell carcinoma , sarcoma , basal cell
CD10 is now commonly used to differentiate atypical fibroxanthoma (AFX) from melanoma, spindle cell and dedifferentiated variants of squamous cell carcinoma and leiomyosarcoma. However, we have encountered CD10‐positive tumors that mimicked AFX but proved to be myxofibrosarcomas. The purpose of this study was to evaluate CD10 expression in a wide range of mesenchymal neoplasms that may involve the skin using tissue microarrays. Our results indicate that in addition to AFX, CD10 expression is common in myxofibrosarcomas, undifferentiated pleomorphic sarcomas, dermatofibromas and dermatofibrosarcoma protuberans. Myxofibrosarcomas commonly present in the skin and may be difficult to distinguish from AFX on small biopsies and CD10 positivity may confound the diagnostic difficulty. Clarke LE, Frauenhoffer E, Fox E, Neves R, Bruggeman RD, Helm KF. CD10‐positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.